RedHill Biopharma Past Earnings Performance
Past criteria checks 0/6
RedHill Biopharma has been growing earnings at an average annual rate of 18.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 0.9% per year.
Key information
18.4%
Earnings growth rate
28.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 0.9% |
Return on equity | -49,465.6% |
Net Margin | -814.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate
Sep 10RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17RedHill: Given Up For Dead
Apr 30RedHill Biopharma: Looking At An Unexciting Dead-End
Dec 30RedHill Biopharma Ltd. (NASDAQ:RDHL) Just Reported, And Analysts Assigned A US$15.79 Price Target
Dec 02Revenue & Expenses Breakdown
How RedHill Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 4 | -30 | 21 | 2 |
31 Mar 24 | 4 | -28 | 25 | 3 |
31 Dec 23 | 7 | 24 | 31 | 4 |
30 Sep 23 | 19 | 34 | 38 | 4 |
30 Jun 23 | 36 | 12 | 46 | 5 |
31 Mar 23 | 52 | -1 | 55 | 5 |
31 Dec 22 | 62 | -72 | 64 | 7 |
30 Sep 22 | 71 | -92 | 69 | 12 |
30 Jun 22 | 75 | -78 | 79 | 16 |
31 Mar 22 | 78 | -95 | 87 | 25 |
31 Dec 21 | 86 | -98 | 88 | 29 |
30 Sep 21 | 85 | -98 | 95 | 30 |
30 Jun 21 | 84 | -95 | 92 | 28 |
31 Mar 21 | 84 | -82 | 82 | 21 |
31 Dec 20 | 64 | -76 | 75 | 16 |
30 Sep 20 | 44 | -64 | 61 | 13 |
30 Jun 20 | 25 | -55 | 48 | 11 |
31 Mar 20 | 6 | -50 | 38 | 15 |
31 Dec 19 | 6 | -42 | 30 | 17 |
30 Sep 19 | 6 | -38 | 25 | 21 |
30 Jun 19 | 7 | -39 | 21 | 25 |
31 Mar 19 | 8 | -39 | 20 | 24 |
31 Dec 18 | 8 | -39 | 20 | 25 |
30 Sep 18 | 9 | -42 | 21 | 27 |
30 Jun 18 | 8 | -47 | 23 | 29 |
31 Mar 18 | 6 | -47 | 23 | 31 |
31 Dec 17 | 4 | -46 | 20 | 33 |
30 Sep 17 | 2 | -43 | 15 | 32 |
30 Jun 17 | 1 | -37 | 10 | 31 |
31 Mar 17 | 0 | -32 | 6 | 29 |
31 Dec 16 | 0 | -29 | 5 | 25 |
30 Sep 16 | 0 | -28 | 6 | 23 |
30 Jun 16 | 0 | -22 | 5 | 20 |
31 Mar 16 | 0 | -22 | 4 | 19 |
31 Dec 15 | 0 | -21 | 4 | 18 |
30 Sep 15 | 0 | -20 | 4 | 17 |
30 Jun 15 | 0 | -21 | 4 | 17 |
31 Mar 15 | 0 | -19 | 4 | 15 |
31 Dec 14 | 7 | -11 | 4 | 13 |
30 Sep 14 | 7 | -9 | 4 | 12 |
30 Jun 14 | 7 | -7 | 3 | 10 |
31 Mar 14 | 7 | -5 | 3 | 8 |
31 Dec 13 | 0 | -11 | 3 | 8 |
30 Sep 13 | 0 | -11 | 3 | 7 |
Quality Earnings: RDHL is currently unprofitable.
Growing Profit Margin: RDHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RDHL is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare RDHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: RDHL has a negative Return on Equity (-49465.57%), as it is currently unprofitable.